Try a new search

Format these results:

Searched for:

in-biosketch:true

person:belsid02

Total Results:

105


Safety Assessment of Ginkgo biloba-Derived Ingredients as Used in Cosmetics

Burnett, Christina L; Bergfeld, Wilma F; Belsito, Donald V; Hill, Ronald A; Klaassen, Curtis D; Liebler, Daniel C; Marks, James G; Shank, Ronald C; Slaga, Thomas J; Snyder, Paul W; Fiume, Monice; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 10 Ginkgo biloba-derived ingredients, which are most frequently reported to function in cosmetics as skin conditioning agents or antioxidants. The Panel reviewed the available data to determine the safety of these ingredients. Because final product formulations may contain multiple botanicals, each containing the same constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. The Panel was concerned about the presence of ginkgolic acid in cosmetics. Industry should use good manufacturing practices to limit impurities. The Panel concluded that 5 Ginkgo biloba leaf-derived ingredients are safe in the present practices of use and concentration described in this safety assessment when formulated to be non-sensitizing; data are insufficient to determine the safety of the remaining 5 ingredients under the intended conditions of use in cosmetic formulations.
PMID: 37930133
ISSN: 1092-874x
CID: 5643382

Safety Assessment of Hops as Used in Cosmetics

Becker, Lillian; Boyer, Ivan; Bergfeld, Wilma F; Belsito, Donald V; Hill, Ronald A; Klaassen, Curtis D; Liebler, Daniel C; Marks, James G; Shank, Ronald C; Slaga, Thomas J; Snyder, Paul W; Fiume, Monice; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of Humulus Lupulus (Hops) Extract (reported functions include antimicrobial agent and hair conditioning agent) and Humulus Lupulus (Hops) Oil (reported function is fragrance). The Panel reviewed the relevant data related to these ingredients. Because final product formulations may contain multiple botanicals, each containing the same constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. For these ingredients, the Panel was concerned about the presence of 8-prenylnaringenin, β-myrcene, and quercetin in cosmetics, which could result in estrogenic effects, dermal irritation, and genotoxicity, respectively. Industry should use current good manufacturing practices to limit impurities and constituents of concern. The Panel concluded that Humulus Lupulus (Hops) Extract and Humulus Lupulus (Hops) Oil are safe in cosmetics in the present practices of use and concentration when formulated to be non-sensitizing.
PMID: 38126727
ISSN: 1092-874x
CID: 5643412

Safety Assessment of Adenosine as Used in Cosmetics

Cherian, Priya; Bergfeld, Wilma F; Belsito, Donald V; Hill, Ronald A; Klaassen, Curtis D; Liebler, Daniel C; Marks, James G; Shank, Ronald C; Slaga, Thomas J; Snyder, Paul W; Fiume, Monice; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of Adenosine, Adenosine Phosphate, Adenosine Triphosphate, Disodium Adenosine Phosphate, and Disodium Adenosine Triphosphate. These ingredients are reported to function in cosmetics as skin-conditioning agents - miscellaneous. The Panel considered the available data and concluded that the five adenosine ingredients reviewed in this report are safe in cosmetics in the present practices of use and concentration described in this safety assessment.
PMID: 38146080
ISSN: 1092-874x
CID: 5643432

Safety Assessment of Trialkyl Trimellitates as Used in Cosmetics

Fiume, Monice M; Bergfeld, Wilma F; Belsito, Donald V; Hill, Ronald A; Klaassen, Curtis D; Liebler, Daniel C; Marks, James G; Shank, Ronald C; Slaga, Thomas J; Snyder, Paul W; Gill, Lillian J; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 5 trialkyl trimellitates. These ingredients, which are all structurally related as alkyl esters of trimellitic acid, are reported to function in cosmetics as skin conditioning agents; 2 of the ingredients are also reported to function in cosmetics as plasticizers. The Panel reviewed the available data to determine the safety of these ingredients, and concluded that the trialkyl trimellitates are safe in the current practices of use and concentration when formulated to be non-irritating.
PMID: 38158838
ISSN: 1092-874x
CID: 5643442

More than just methylisothiazolinone: Retrospective analysis of patients with isothiazolinone allergy in North America, 2017-2020

Reeder, Margo J; Zhang, Donglin; Aravamuthan, Srikanth R; Warshaw, Erin M; DeKoven, Joel G; Silverberg, Jonathan I; Adler, Brandon L; Atwater, Amber R; Taylor, James S; Houle, Marie-Claude; Belsito, Donald V; Yu, Jiade; Botto, Nina; Mowad, Christen M; Dunnick, Cory A; DeLeo, Vincent A; Pratt, Melanie D
BACKGROUND:Isothiazolinones are a common cause of allergic contact dermatitis. OBJECTIVE:To examine the prevalence of positive patch test reactions to isothiazolinones from 2017-2020 and characterize isothiazolinone-allergic (Is+) patients compared with isothiazolinone nonallergic (Is-) patients. METHODS:Retrospective cross-sectional analysis of 9028 patients patch tested to methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) 0.02% aqueous, MI 0.2% aqueous, benzisothiazolinone (BIT) 0.1% petrolatum, and/or octylisothiazolinone (OIT) 0.025% petrolatum. Prevalence, reaction strength, concurrent reactions, clinical relevance, and source of allergens were tabulated. RESULTS:In total, 21.9% (1976/9028) of patients had a positive reaction to 1 or more isothiazolinones. Positivity to MI was 14.4% (1296/9012), MCI/MI was 10.0% (903/9017), BIT was 8.6% (777/9018), and OIT was 05% (49/9028). Compared with Is-, Is+ patients were more likely to have occupational skin disease (16.5% vs 10.3%, P <.001), primary hand dermatitis (30.2% vs 19.7%, P <.001), and be >40 years (73.1% vs 61.9%, P <.001). Positive patch test reactions to >1 isothiazolinone occurred in 44.1% (871/1976) of Is+ patients. Testing solely to MCI/MI would miss 47.3% (611/1292) of MI and 60.1% (466/776) of BIT allergic reactions. LIMITATIONS/CONCLUSIONS:Retrospective cross-sectional study design and lack of follow-up data. CONCLUSION/CONCLUSIONS:Sensitization to isothiazolinones is high and concurrent sensitization to multiple isothiazolinone allergens is common.
PMID: 37879460
ISSN: 1097-6787
CID: 5643372

Safety Assessment of Butyrospermum parkii (Shea)-Derived Ingredients as Used in Cosmetics

Burnett, Christina L; Bergfeld, Wilma F; Belsito, Donald V; Hill, Ronald A; Klaassen, Curtis D; Liebler, Daniel C; Marks, James G; Shank, Ronald C; Slaga, Thomas J; Snyder, Paul W; Fiume, Monice; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 13 Butyrospermum parkii (shea)-derived ingredients, which are most frequently reported to function in cosmetics as skin and hair conditioning agents. The Panel reviewed the available data to determine the safety of these ingredients. Because final product formulations may contain multiple botanicals, each containing similar constituents of concern, formulators are advised to be aware of these constituents and to avoid reaching levels that may be hazardous to consumers. Industry should use good manufacturing practices to limit impurities that could be present in botanical ingredients. The Panel concluded that these ingredients are safe in the present practices of use and concentration when formulated to be non-sensitizing.
PMID: 38166445
ISSN: 1092-874x
CID: 5643452

Allergic or Not: Final Interpretation of Doubtful Patch Test Reactions From the North American Contact Dermatitis Group, 2019-2020

Reeder, Margo J; Nihal, Aman; Aravamuthan, Srikanth R; Warshaw, Erin M; DeKoven, Joel G; Atwater, Amber R; Houle, Marie-Claude; Adler, Brandon L; Silverberg, Jonathan I; Taylor, James S; Pratt, Melanie D; Belsito, Donald V; Yu, Jiade; Botto, Nina B; Mowad, Chris M; Dunnick, Cory A; DeLeo, Vincent A
PMID: 38320244
ISSN: 2162-5220
CID: 5643482

Patch Test Results Among Older Adults: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2009-2020)

Yu, JiaDe; Johnson, Hadley; DeKoven, Joel G; Warshaw, Erin M; Taylor, James S; Belsito, Donald V; Adler, Brandon L; Silverberg, Jonathan I; Atwater, Amber R; Reeder, Margo J; Botto, Nina; Houle, Marie-Claude; Mowad, Christen M; Pratt, Melanie D; Dunnick, Cory A
PMID: 37590477
ISSN: 2162-5220
CID: 5642972

Patch Testing With Nickel, Cobalt, and Chromium in Patients With Suspected Allergic Contact Dermatitis

Silverberg, Jonathan I; Patel, Nisha; Warshaw, Erin M; DeKoven, Joel G; Belsito, Donald V; Atwater, Amber R; Taylor, James S; Sasseville, Denis; Reeder, Margo J; Houle, Marie-Claude; DeLeo, Vincent A; Maibach, Howard I; Fowler, Joseph F; Zug, Kathryn A; Pratt, Melanie D; Yu, JiaDe; Mowad, Christen M; Botto, Nina C; Adler, Brandon L
PMID: 38052041
ISSN: 2162-5220
CID: 5643402

Mink Oil

Tucker, Regina; Bergfeld, Wilma F; Belsito, Donald V; Cohen, David E; Klaassen, Curtis D; Liebler, Daniel C; Rettie, Allan E; Ross, David; Slaga, Thomas J; Snyder, Paul W; Tilton, Susan; Fiume, Monice; Heldreth, Bart
The Expert Panel for Cosmetic Ingredient Safety reviewed updated information that has become available since their original assessment from 1998, along with updated information regarding product types, and frequency and concentrations of use, and reaffirmed their original conclusion that Mink Oil is safe as a cosmetic ingredient in the practices of use and concentration as described in this report.
PMID: 37751389
ISSN: 1092-874x
CID: 5643012